FindTrial
Sign In

Role of ripasudil eye drops in cataract surgery

Therapeutic Role of Ripasudil 0.4 % for corneal endothelial protection in phacoemulsification of hard cataracts - A randomized controlled trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/02/031017
Enrollment
40
Registered
2021-02-04
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: H188- Other specified disorders of cornea

Interventions

Intervention1: Ripasudil eye drops 0.4%: Ripasudil eye drops 0.4% 3 times per day for phacoemulcification in hard cataracts, given perioperatively for a period of 10 days Control Intervention1: carbox

Sponsors

Srikiran eye institute
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: senile cataract patients with grade 3 and above(LOCS 3 Grading) ,willing to participate in study

Exclusion criteria

Exclusion criteria: pregnent and lactating mothers ,complicated cataracts , one eyed patients ,intra operative complications which may influence the outcome

Design outcomes

Primary

MeasureTime frame
post operative endothelial cell countTimepoint: 1 week , 1 month and 3 months—

Secondary

MeasureTime frame
visual acuity and IOPTimepoint: 1 week , 1 month and 3 months—

Countries

India

Contacts

Public ContactDr madhu uddaraju

srikiran eye hospital

eyedrmadhu@gmail.com9676743333

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026